<--- Back to Details
First PageDocument Content
Immunosuppressants / Medicine / Cytokines / Autoimmune diseases / Treatment of multiple sclerosis / Glatiramer acetate / Natalizumab / Fingolimod / Interferon beta-1a / Immunology / Immune system / Multiple sclerosis
Date: 2015-04-22 23:39:46
Immunosuppressants
Medicine
Cytokines
Autoimmune diseases
Treatment of multiple sclerosis
Glatiramer acetate
Natalizumab
Fingolimod
Interferon beta-1a
Immunology
Immune system
Multiple sclerosis

Microsoft Word - Sanofi- 5.1 alemtuzumabPSD final.docx

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 205,06 KB

Share Document on Facebook

Similar Documents

Multiple sclerosis / Medicine / Immunology / Clinical medicine / Autoimmune diseases / Neurological disorders / Neurology / Management of multiple sclerosis / Glatiramer acetate / Immunosuppressants / McDonald criteria / Diagnostic criteria for MS

Guideline on clinical investigation of medicinal products for the treatment of Multiple Sclerosis rev. 2

DocID: 1rmwo - View Document

Cytokines / Interferon beta-1a / Lifeline / TTY / Glatiramer acetate

PDF Document

DocID: 1rhTx - View Document

Cytokines / Interferon beta-1a / Glatiramer acetate / Natalizumab

PDF Document

DocID: 1ptj0 - View Document

PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr COPAXONE® Glatiramer acetate

DocID: 1kIzm - View Document

Autoimmune diseases / Medicine / Immunosuppressants / Neurological disorders / Treatment of multiple sclerosis / Glatiramer acetate / Natalizumab / Mitoxantrone / Fingolimod / Multiple sclerosis / Immunology / Immune system

Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators

DocID: 1fWCE - View Document